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On the membrane surface of resting platelets exists a factor capable of promoting the conversion of plasma von Wille- 
brand factor from low and intermediate molecular mass to high molecular mass polymers. The process is accompanied 
by a parallel increase in the von Willebrand factor activity. This could be a regulatory system for the molecular mass 
distribution of von Willebrand factor during its lifetime in plasma. Glycoprotein Ib of the platelet membrane appears 
not to be involved in the process. 
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1. INTRODUCTION 
The von Willebrand disease is an autosomic 
coagulation disorder due to a quali- and/or quan- 
titative deficiency of the von Willebrand factor 
(vWF), a large glycoprotein produced by the en- 
dothelial cells and megacaryocytes [1-3]. In 
plasma, vWF circulates as a heterogeneous mixture 
of disulfide-bridged polymers ranging from dimers 
(Mr 25X104) to multimers (Mr>2× 107) and its 
role is to promote the initial step in hemostatic plug 
formation [4] by interacting with the suben- 
dothelial structures (collagen) of injured vessel and 
with the glycoprotein IIb-IIIa of activated platelets 
[5,6]. In the presence of the antibiotic ristocetin, 
vWF is capable of interacting with resting platelets 
too: in this case the platelet membrane glycopro- 
tein Ib is responsible for the interaction with the 
ristocetin-vWF complex [7-11] by which platelets 
are activated and aggregate. Glycoprotein Ib re- 
tains the capability to interact with the ristocetin- 
vWF complex also when platelets are metabolically 
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inactive such as after treatment with formaldehyde 
[12,13]; in this case agglutination of FFP occurs. 
Both the physiological interaction of vWF with 
activated platelets, and the non-physiological in- 
teraction of the ristocetin-vWF complex with 
resting or inactivated platelets, strongly depend on 
the molecular mass of the polymers, the highest ac- 
tivity being shown by the largest molecules. 
A lot of information exists indicating that the 
vWF molecules produced by the endothelial cells 
are stored into the Weibel-Palade bodies as a mix- 
ture containing all the polymeric forms, but it is 
not known, to date, whether this is the only way by 
which the HMW polymers are produced, or 
whether polymerization may also occur after the 
secretion of glycoprotein into blood [14-16]. The 
problem becomes more puzzling because of the re- 
cent observation [17] that the proteolytic leavage 
of the precursor (pro-vWF) seems not to be essen- 
tial for the multimers formation. 
In the present paper we show that on the resting 
platelet membrane surface there is a factor capable 
of promoting the conversion of vWF from low and 
intermediate molecular mass to high molecular 
mass polymers with a consequent increase in the 
vWF activity. 
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2. MATERIALS AND METHODS 
2.1 Materials 
All reagents were analytical grade. Human platelet poor 
plasma (PPP) was prepared by double centrifugation (2000 × g; 
15 rain) of citrate (0.38°70) added to fresh blood samples from 
volunteers. Platelet rich plasma (PRP) was obtained by double 
centrifugation of citrate added to blood (200xg; 8 min). 
Washed platelets (WP) were prepared immediately before use by 
centrifugation of PRP (3000xg; 15 min) followed by three 
washing cycles of the pellet with 10 mM Tris, 1 mM EDTA, pH 
7.5, buffer (Tris-EDTA buffer): from 40 ml of fresh blood we 
usually obtained 10 ml of washed platelets ( -4x  103 WP//~I). 
Formaldehyde-fixed platelets (FFP) were prepared by one hour 
preincubation f PRP suspensions (10 ml) at 37°C, followed by 
centrifugation (2500 × g; 15 min) and resuspension f the pellet 
in 10 ml of Tris-EDTA buffer containing 2070 formaldehyde; 
after 48 h incubation at 4°C the suspension was centrifuged 
(2500 x g; 15 min) and the pellet was resuspended in Tris-EDTA 
buffer giving 3 x 105 FFP/#I (10-12 ml) and stored at 4°C. In- 
cubations of PPP samples with FFP or WP were performed by 
centrifuging (3000 x g; 15 rain) the desired amount of platelets 
from the storage buffer and gently resuspending the pellet in the 
required volume of plasma to be treated. 
The experiments requiring WP were preceded by a control on 
the integrity of platelets by suspending them (3 × l0 s WP/ml) in 
200 ttl of PPP in the aggregometer vessel and following the ag- 
gregation process induced by 2 ttM ADP. Parallel to these x- 
periments, aggregometric controls were routinely performed in
order to check whether incidental activation of WP occurred 
during incubations. 
2.2. vWF activity in plasma 
200 #1 of FFP suspension (3 x 105 FFP//d), supplemented with 
1 mg/ml ristocetin, were preincubated 3 min at 37°C into the ag- 
gregometer vessel under stirring, after which 50 td of the PPP to 
be tested were added; the aggregometer (Menarini) recorded the 
increase in transmittance, due to the agglutination of platelets, 
vs time. The slope of the initial agglutination time course was 
proportional to the activity of the vWF in the sample. We 
assumed 10007o activity to be that obtained for a PPP sample 
from a pool of blood samples from voluntary donors under the 
indicated test conditions. 
2.3 Agarose gel electrophoresis, transblotting, staining 
Gel electrophoresis was performed substantially as in [18] 
with some modifications. Gels, 1 mm thick, were 10x 10 cm 
size, the stacking and the running parts were 0.75% and 1.7507o 
agarose and were 2.5 cm and 7.5 cm in length, respectively; sam- 
ple wells (2 x 0.2 cm) were cut in the stacking el at 1 cm from 
the interface. Plasma to be investigated was diluted 5-fold with 
Tris-EDTA buffer adjusted to pH 8.0 and containing 2°70 SDS, 
8 M urea and 0.01% bromophenol blue as tracking dye. After 
20 min incubation at 60°C, 20 #1 samples were applied to each 
well and electrophoresis tarted at 20 mA constant current. 
After the samples had moved out of the wells, these were filled 
with stacking el suspension and the current was decreased to4 
mA. Electrophoresis was stopped when the dye reached the 
anode end of the gel (usually 14 h). After the run the gel was 
transblotted onto a nitrocellulose sheet (Bio-Rad, 10x 10 cm, 
0.22/~m) by a standard transblot chamber (Bio-Rad) and follow- 
ing the recommended procedure (24 h run; 200 mA constant 
current; 4°C temperature; running buffer, 15.6 mM Tris, 120 
mM glycine, pH 8.3, containing 0.05070 SDS, 20% methanol). 
The nitrocellulose heet was treated (30 min) with fixing buffer 
(2-propanol/acetic acid/water, 25:10:65), washed three times 
with Tris-NaCl buffer (50 mM Tris, 150 mM NaCI, pH 7.5), 
saturated by incubation (30 min) in Tris-NaC1 buffer containing 
1 ~70 bovine serum albumin and washed three times with Tris- 
NaC1 buffer containing 1°70 Triton X-100. Staining was ob- 
tained by a 4 h incubation of the nitrocellulose heet with perox- 
idase-conjugated anti-human vWF rabbit antiserum (DAKO) 
diluted 1:125 with Tris-NaC1 buffer containing 1°70 Triton 
X-100, followed by four washing cycles with the same buffer 
and four washing cycles with Tris-NaC1 buffer. The last washing 
bath was supplemented, in the dark, with 0.5 mg/ml 
4-chloro-l-naphthol (predissolved in methanol) and 5 mM 
hydrogen peroxide. The incubation was stopped after 20 rain by 
repeated washings with distilled water. After air drying, the 
nitrocellulose heet was photographed. 
3. RESULTS AND DISCUSSION 
A typical PPP from healthy donors shows the 
molecular mass distribution of vWF polymers 
represented in fig. 1 (lane 1), the activity (as defined 
in section 2.2) of which was taken as 10001o. In the 
presence of ristocetin and FFP, a ristocetin-vWF 
complex was formed capable of interacting with 
the membrane glycoprotein Ib of FFP [12,13] by 
which agglutination occurred and, consequently, 
the removal of vWF bound to platelets from the 
medium was possible by centrifugation. As shown 
in lane 2, by an agglutination-centrifugation treat- 
ment, the high molecular mass vWF polymers 
(HMW-vWF) were removed from plasma with a 
drop of activity to 25°70 with respect o sample 1. 
The intermediate molecular mass polymers (IMW- 
vWF) were removed from plasma by a second iden- 
tical treatment by which only the low molecular 
mass polymers (LMW-vWF, i.e. dimers and 
tetramers) remained in the medium with an activity 
near zero (lane 3). 
A PPP sample (fig.2, lane 1), subjected to an ag- 
glutination-centrifugation treatment toremove the 
HMW-vWF polymers, was incubated with WP and 
subsequently centrifuged. In the supernatant ob- 
tained after an hour of incubation (lane 3), the 
trace corresponding to the highest polymer of lane 
2 completely disappeared and, after two hours of 
incubation, a sharp decrease in the intensity of all 
traces was observed. This result is interpreted as a 
consequence of the concurrent effects of WP and 
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Fig.1. Molecular mass distribution of vWF in PPP before and 
after two subsequent agglutination treatments with ristocetin 
and FFP. PPP (sample 1) supplemented with 6 x 108 FFP/ml 
and 2 mg/ml ristocetin was incubated 3 min at 37°C under stir- 
ring and centrifuged (3000 xg, 15 min). The supernatant (sam- 
ple 2) was subjected to a second identical treatment and the 
supernatant thereof was sample 3. Aliquots of samples were 
employed for electrophoresis and the vWF activity assays. 
r istocetin on vWF molecules. We propose that on 
the membrane surface of  resting platelets there is a 
factor capable of  promot ing the organizat ion of  
IMW-  and LMW-vWF polymers toward  structures 
having a higher molecular  mass; ristocetin, present 
in samples 3 and 4 because of  the large excess 
employed in the agglut inat ion process, on com- 
plexing with the newly formed HMW-vWF 
polymers allows the act iv itat ion and the conse- 
quent aggregation of  WP [7-11]. This idea is in ac- 
cordance with the paral lel  decrease in the vWF ac- 
t ivity in the supernatants ( from 25% of sample 2 to 
12% and 7°7o after one and two hours of  incuba- 
t ion, respectively). 
Direct evidence of  the capabi l i ty of  resting 
platelets to promote the associat ion o f  LMW-  and 
IMW-vWF polymers to give larger and more active 
species, was obtained f rom the experiment shown 
in fig.3 in which a PPP  sample (lane 1, 100% ac- 
tivity), after an agglut inat ion-centr i fugat ion reat- 
ment (lane 2, 25% activity), was subjected to ex- 
haustive dialysis to remove the ristocetin excess 
before incubat ion with WP.  Under these condi- 
t ions, with increasing incubat ion time, a pro-  
gressive decrease in the concentrat ion of  LMW-  
and IMF-vWF polymers was observed, accom- 
1 2 3 ,t 
Fig.2. Effect of washed platelets in the presence of ristocetin on 
the molecular mass distribution of vWF in PPP. PPP (sample 
1) was subjected to one agglutination-centrifugation treatment 
like those of fig. 1. The supernatant (sample 2) supplemented 
with 2.5 × 108 WP/ml was incubated at 37°C for 1 or 2 h and 
centrifuged before assays (samples 3and 4, respectively). 
panied with the progressive appearance of  signifi- 
cant amounts o f  HMW species (cf. lane 3 and 4 
with lane 2) and with a dramat ic  increase in the 
vWF activity (43% in sample 3 and 65% in sample 
4 corresponding to 30 and 60 min incubation,  
respectively). The absence of  ristocetin, in this 
'1 21 ¸ ' 4 
Fig.3. Effect of washed platelets in the absence of ristocetin on 
the molecular mass distribution of vWF in PPP. PPP (sample 
1) was subjected to one agglutination-centrifugation treatment 
like those of fig. 1. The supernatant was dialyzed against Tris- 
NaCI buffer (3 cycles, 1 h, 500 ml) at 4°C. The dialysate (sample 
2) supplemented with 2.5 × 108 WP/ml was incubated at room 
temperature 30 and 60 min and centrifuged before assays 
(samples 3and 4, respectively). 
364 
Volume 249, number 2 FEBS LETTERS June 1989 
case, allows the accumulation of the species that, in 
the experiment o f  fig.2, were removed because of 
the aggregation process. 
The possibility that, in the experiment shown in 
fig.3, the HMW-vWF polymers present in the 
supernatants after incubations could be due to the 
dismission of the content of the platelets oz- 
granules by an incidental activation is to be ex- 
cluded either because of our routine aggregometric 
control during incubation, and because, in this 
hypothesis, the platelet activation should have been 
followed by aggregation [7-11], by which, after 
centrifugation, the electrophoretic pattern and the 
activity assay of the supernatants should have been 
similar to those of the experiment represented in
fig.2. 
A PPP sample (fig.4, lane 1), subjected to an ag- 
glutination-centrifugation reatment (lane 2, 22% 
activity with respect o sample 1), was incubated 
for two hours in the presence of 1 mg/ml ristocetin. 
After centrifugation, the supernatant (lane 3) 
showed an electrophoretic pattern and an activity 
identical to sample 2, indicating that the conver- 
sion of vWF polymers observed under the condi- 
tions of experiments shown in figs2 and 3 was not 
due to a spontaneous a sociation or to a direct ef- 
fect of ristocetin on the vWF molecules, the only 
function of the antibiotic being to complex with the 
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Fig.4. Effect of ristocetin and FFP on the molecular mass 
distribution of vWF in PPP. PPP (sample 1) was subjected to 
one agglutination-centrifugation treatment like those of fig. 1. 
The supernatant, dialyzed as described in fig.3 (sample 2), was 
supplemented with 1 mg/ml ristocetin (sample 3) or with 6 x 10 s 
FFP/ml  (sample 4), incubated 2 h at 37°C and centrifuged 
before assays. 
1 2 3 4 
Fig.5. Effect of red and red plus white cells in the presence of 
ristocetin on the molecular mass distribution of vWF in PPP. 
PPP (sample 1) was subjected to one agglutination-centrifuga- 
tion treatment like those of fig. 1 and the supernatant (sample 2) 
was supplemented with 1 mg/ml ristocetin. Aliquots (300 #1) 
were incubated at room temperature in the presence of red (sam- 
ple 3) or red plus white cells (sample 4) (each obtained from 750 
#1 of fresh blood) and centrifuged before assays. 
polymers, allowing them to interact with the 
platelet glycoprotein Ib. 
That the capability to convert he vWF polymers 
is a specific property of the platelet membrane sur- 
face was confirmed by the experiment shown in 
fig.5: aliquots of a PPP sample (lane 1), subjected 
to an agglutination-centrifugation treatment (lane 
2, 25°70 activity) were supplemented with 1 mg/ml 
ristocetin and incubated one hour in the presence 
of red (lane 3) or red plus white cells (lane 4) (each 
obtained from 750 #l of fresh blood); after cen- 
trifugation both samples were shown to be un- 
changed in both the electrophoretic pattern and the 
vWF activity. 
This property of the platelet membrane was lost 
when platelets were inactivated by the for- 
maldehyde treatment: in fact, a PPP sample sub- 
jected to an agglutination-centrifugation treatment 
followed by dialysis to remove the ristocetin excess 
(fig.4, lane 2), was incubated for two hours in the 
presence of FFP; after centrifugation, the superna- 
tant was unchanged inboth the vWF activity (2207o) 
and the electrophoretic pattern (lane 4). 
CONCLUDING REMARKS 
In the present work, it is stated for the first time 
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that,  on the membrane surface of  resting intact 
platelets, the conversion of  vWF from LMW-  and 
IMW-  to HMW-vWF polymers occurs. It is known 
that the vWF content of  the a-granules of  platelets 
is rich in HMW components and that in the 
Weibe l -Pa lade  bodies of  the endothel ial  ceils vWF 
is stored as a set of  polymers of  varying molecular  
mass. Nevertheless, there are no data on the ex- 
istence of  a funct ion for the LMW component  in 
p lasma, It is possible that the process occurr ing on 
the platelet membrane surface is part  of  a 
mechanism regulating the vWF molecular mass 
distr ibut ion during its l i fetime in plasma, 
Speculat ion on the possible involvement of  the 
glycoprotein Ib in the process described here can be 
attempted.  The interact ion between vWF and 
glycoprotein Ib occurs only when the former is 
complexed with ristocetin. We do not know 
whether this property  has some physiological  
meaning,  especially, since it is retained when 
platelets are metabol ical ly  inactive, whereas the 
capabi l i ty  to promote  the conversion of  vWF 
polymers is lost (fig.4). Two possibil it ies arise: or 
g lycoprotein Ib is not involved in the polymer con- 
version, or the two propert ies are located in two 
dist inct domains of  the protein.  
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